

PATENT
ATTORNEY DOCKET NO.: TNX00-03
Custom r No.: 26839

#6/A
JM
7/16/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
THOMAS et al.

Serial No.: 09/773,866

Filed: February 1, 2001

For: CD40 BINDING APS-ACTIVATING
MOLECULES

Group Art Unit: 1632

Examiner: P. Gambel

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

In response to the Restriction Requirement dated June 13, 2002,
Applicants hereby elect Group I, claims 1-16, directed to agonistic CD40-specific
molecules/antibodies and cell lines. If there are any fees due in connection with
this response, please charge our deposit account number 20-0087.

Please amend the specification as follows:

IN THE CLAIMS:

6. The agonist anti-CD40 molecule of any one of claims 1, 2, 3 or 4 which
completely inhibits CD40L binding to CD40.
7. A composition comprising a combination of at least one of the following:
- a) An agonist anti-CD40 molecule that can bind to and stimulate
professional or non-professional human APCs;
 - b) An agonist anti-CD40 molecule that enhances the stimulatory effect of
CD40L on CD40 positive cells;

A1